NCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 22 versions: 15 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 28 words
- Enrollment closed, study ongoing
- Final enrollment: 51 participants (planned 58)
- Site details revised at 8 of 8 sites
- Notable Primary and study completion dates: Jul 2026 to Jul 2027
- Site details revised at 2 of 8 sites
- Notable Primary and study completion dates: Jul 2025 to Jul 2026v19
- Notable Primary and study completion dates: Jul 2024 to Jul 2025v15
- Notable Primary and study completion dates: Jul 2023 to Jul 2024
- Site contacts updated at 7 of 8 sites
Show 9 earlier versionsHide 9 earlier versions
- Notable Eligibility criteria expanded, about 15 wordsv11
- Notable Primary and study completion dates: Jul 2022 to Jul 2023v10
- Notable Eligibility criteria expanded, about 18 wordsv9
- Notable Primary and study completion dates: Jul 2021 to Jul 2022
- Site contacts updated at 7 of 8 sites
- Notable Primary and study completion dates: Jul 2020 to Jul 2021v7
- Notable Eligibility criteria shortened, about 3 wordsv6
- Minor Study sites revised (8)v5
- Notable Eligibility criteria expanded, about 87 words
- Study sites: 7 to 8
- Study title expanded, about 2 words
- Minor Site details revised at 1 of 7 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. As of October 2020, the Simon two stage design for Cohort 1 has restarted at the 1.2 mg/kg dose.
Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.
Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.
Drugs: brentuximab vedotin
Sites
8 sites in 1 country